We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Lecture outline
- The hallmarks of cancer
- How do we get to cancer?
- Where do mutations count?
- Examples of oncogenes and tumour suppressors
- What makes these genes so special?
- How do these genes have wide ranging effects?
- One example among many: AKT
- Association between oncogenes and cancers
- How can signalling be perverted in cancer? (1)
- How can signalling be perverted in cancer? (2)
- How can signalling be perverted in cancer? (3)
- The role of the microenvironment
- How we exploit the hallmarks for therapy?
- Why is the driver oncogene important
- Revolutionary treatments
- Why do we still struggle to cure cancer? (1)
- Why do we still struggle to cure cancer? (2)
- Re-awakening the immune system
- What is next for cancer research?
- If you want to learn more about cancer research
Topics Covered
- Present general hallmarks of cancer
- Explain how cancer is initiated through activation of oncogenes and deactivation of tumour suppressors
- Highlight what makes these oncogenes and tumour suppressors so special
- Show different ways in which these proteins can modify cell signalling to lead to cancer
- Introduce the notion that cancer is not only about the cancer cell but also about the environment
- Give examples of how we can exploit this combined knowledge to develop cancer therapeutics and the associated challenges
Talk Citation
Pardo, O. (2019, January 31). The biology of cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 7, 2024, from https://doi.org/10.69645/WDSZ2612.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Olivier Pardo, Consulting Fees (e.g., advisory boards), Honoraria: Clyzlab
Transcript
Please wait while the transcript is being prepared...
0:00
Hi. My name is Dr. Pardo,
a team leader at the Division of Cancer at Imperial College
and today, I'm going to tell you about the biology of cancer.
This is a basic lecture on cancer biology,
so this is not going to go extensively
through all the subjects relating to cancer biology,
but just introduce some notions that I hope you will find interesting.
0:26
So, what exactly shall we touch on in this lecture?
The first thing that I have to say is that we are assuming
here that you already know about cancer as a disease,
meaning what is cancer versus other diseases.
Therefore, what we're going to more specifically focus on here today is to present
general hallmarks of cancer and
explain how these phenotypes relate to cancer development,
explain also how cancer is initiated through activations of particular genes
called oncogenes and deactivation of other genes called tumor suppressors.
We're going to also explain what makes this gene so
special as compared to other genes in the genome,
and show the different ways that cancer cells use
to rewire cell signaling in order to promote tumor development.
Also, I will introduce the idea that a tumor is not only about the cancer cell,
but also about the microenvironment so what surrounds the tumor.
Finally, I'm going to give you examples of how we use
this knowledge to develop a new therapeutic strategy,
but also what the challenges are in current therapy development.